Tubulis raises €10.7M Series A round

The funding will accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and support the further growth of the company, specifically moving the first two selected ADC candidates towards clinical validation.

Source: https://www.tubulis.com/tubulis-raises-e10-7-m-series-a-to-advance-development-of-a-new-generation-of-antibody-drug-conjugates/